이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Amedisys 관리

관리 기준 확인 1/4

Amedisys' CEO는 Richard Ashworth, Apr2023 에 임명되었습니다 의 임기는 1.33 년입니다. 총 연간 보상은 $ 16.97M, 4.1% 로 구성됩니다. 4.1% 급여 및 95.9% 보너스(회사 주식 및 옵션 포함). 는 MX$ 54.42M 가치에 해당하는 회사 주식의 0.088% 직접 소유합니다. 54.42M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 4.8 년입니다.

주요 정보

Richard Ashworth

최고 경영자

US$17.0m

총 보상

CEO 급여 비율	4.1%
CEO 임기	1.4yrs
CEO 소유권	0.09%
경영진 평균 재임 기간	1.7yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Richard Ashworth 의 보수는 Amedisys 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	US$92m
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$17m	US$692k	-US$10m

보상 대 시장: Richard 의 총 보상 ($USD 16.97M )은 MX 시장( $USD 1.68M ).

보상과 수익: Richard 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Richard Ashworth (49 yo)

1.4yrs

테뉴어

US$16,974,025

보상

Mr. Richard M. Ashworth served as Director at Tivity Health, Inc. since June 1, 2020 until April 2023 and had been its President since June 1, 2020 and served as its Chief Executive Officer since June 1, 2...

리더십 팀

이름	위치	테뉴어	보상	소유권
Richard Ashworth	President	1.4yrs	US$16.97m	0.088% $ 54.8m
Scott Ginn	Executive VP	6.9yrs	US$4.45m	0.077% $ 47.9m
Denise Bohnert	Chief Compliance Officer	5yrs	US$1.28m	데이터 없음
Nick Muscato	Chief Strategy Officer	no data	US$1.37m	0.0065% $ 4.1m
Allyson Guidroz	Chief Accounting Officer & Principal Accounting Officer	1.1yrs	데이터 없음	0.0097% $ 6.0m
Pete Hartley	CTO & Senior VP of Business Operations Systems	no data	데이터 없음	데이터 없음
Jennifer Griffin	Senior VP	1.9yrs	데이터 없음	데이터 없음
Kendra Kimmons	VP of Marketing & Communications & Media Relations	no data	데이터 없음	데이터 없음
Caitlin Franklin	Acting Chief People Officer	less than a year	데이터 없음	데이터 없음
Francis Mayer	Senior Vice President of Development	no data	데이터 없음	데이터 없음

1.7yrs

평균 재임 기간

47.5yo

평균 연령

경험이 풍부한 관리: AMED * 의 관리팀은 경험 (평균 재직 기간 1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Richard Ashworth	President	1.4yrs	US$16.97m	0.088% $ 54.8m
Paul Kusserow	Chairman	9.8yrs	US$4.00m	1.33% $ 830.8m
Bruce Perkins	Independent Director	9.4yrs	US$267.62k	0.063% $ 39.5m
Vickie Capps	Independent Director	4.8yrs	US$277.62k	0.020% $ 12.3m
Molly Coye	Independent Director	4.8yrs	US$267.62k	0.017% $ 10.4m
Julie Klapstein	Lead Independent DIrector	8.4yrs	US$282.62k	0.039% $ 24.1m
Jeffrey Rideout	Independent Director	8.4yrs	US$267.62k	0.018% $ 11.4m
Teresa Kline	Independent Director	4.8yrs	US$272.62k	0.020% $ 12.3m
Ivanetta Samuels	Independent Director	3.8yrs	US$252.62k	0.013% $ 8.1m

4.8yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: AMED * 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

Amedisys 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Recent updates

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Insufficient new directors

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Insufficient new directors

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

High number of new directors

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

High number of new directors

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

High number of new directors

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

High number of new directors

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

High number of new directors

Investor sentiment deteriorated over the past week

Lead Independent Director recently bought Mex$3.0m worth of stock

Third quarter 2021 earnings released: EPS US$1.38 (vs US$2.20 in 3Q 2020)

Investor sentiment improved over the past week

High number of new directors

High number of new directors

Independent Director recently sold Mex$42m worth of stock

Second quarter 2021 earnings released: EPS US$2.46 (vs US$1.07 in 2Q 2020)

Investor sentiment deteriorated over the past week

High number of new directors

President & COO recently sold Mex$1.5m worth of stock

Amedisys, Inc. (NasdaqGS:AMED) entered into an Agreement to acquire Contessa Health, Inc. for $250 million.

Amedisys, Inc. (NasdaqGS:AMED) entered into a definitive agreement to acquire Home Health and Hospice Operations of Visiting Nurse Association.

Insider recently sold Mex$10m worth of stock

Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$1.52 (vs US$0.98 in 1Q 2020)

Amedisys, Inc. and Sound Physicians to Launch Home Health Advanced Pilot Program

Independent Director recently bought Mex$5.3m worth of stock

Revenue misses expectations

Full year 2020 earnings released: EPS US$5.64 (vs US$3.95 in FY 2019)

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Dynamic Index

Amedisys, Inc. and Option Care Health Inc. Collaborate to Provide Innovative COVID Therapy Access Model

Ivanetta Davis Samuels Joins Amedisys, Inc.'s Board of Director

Amedisys, Inc. to Report Q3, 2020 Results on Oct 28, 2020

Amedisys, Inc. to Report Q2, 2020 Results on Jul 28, 2020

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Growth-Defensive Index

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Defensive Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀